SCHEMBL10137837

SCHEMBL10137837

CC(C)CCCNC(=O)CCCC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.50
PKM P14618 1/20 0.50
TSHR P16473 2/20 0.49
HPGD P15428 1/20 0.48
EPHX2 P34913 3/20 0.47
ALDH1A1 P00352 1/20 0.46
MEN1 O00255 1/20 0.45
MAPT P10636 1/20 0.45
KMT2A Q03164 1/20 0.45
SLC6A5 Q9Y345 1/20 0.45
PLA2G10 O15496 1/20 0.45
CNR1 P21554 1/20 0.44
KDM4E B2RXH2 1/20 0.44
ADRA1A P35348 1/20 0.44
KDM4C Q9H3R0 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10174293 0.95 LMNA (0.51) LMNAPKMTSHRHPGDEPHX2
SCHEMBL21675612 0.91 ALDH1A1 (0.52) LMNAPKMHPGDEPHX2ALDH1A1
SCHEMBL9789508 0.89 EPHX2 (0.56) LMNAPKMTSHRHPGDEPHX2
SCHEMBL599560 0.89 EPHX2 (0.56) LMNAPKMTSHRHPGDEPHX2
SCHEMBL8576664 0.89 EPHX2 (0.56) LMNAPKMTSHRHPGDEPHX2
SCHEMBL23471810 0.86 ALDH1A1 (0.50) LMNAPKMTSHRHPGDALDH1A1
SCHEMBL13688469 0.85 ALDH1A1 (0.50) LMNAPKMTSHRHPGDEPHX2
SCHEMBL16248615 0.84 ALDH1A1 (0.57) LMNAPKMTSHRHPGDALDH1A1
SCHEMBL21675625 0.84 KDM4C (0.50) LMNAPKMHPGDEPHX2ALDH1A1
SCHEMBL9259832 0.84 ADRA1A (0.56) LMNAPKMEPHX2ALDH1A1PLA2G10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43298-E1 Peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION (US) 2012-04-03 US disclosed
US-20110117057-A1 NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS SCHERING CORPORATION (US) 2011-05-19 US disclosed
US-7595299-B2 Peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION (US) 2009-09-29 US disclosed
US-7592316-B2 Peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION (US) 2009-09-22 US disclosed
US-20070232549-A1 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION 2007-10-04 US disclosed
US-7244721-B2 Peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION (US) 2007-07-17 US disclosed
US-20070032433-A1 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. 2007-02-08 US disclosed
US-7169760-B2 Peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION (US) 2007-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232549-A1 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus HPN, TMPRSS15, VIP LMNA 3429/4885PKM 3364/4885TSHR 4691/4885
US-20110117057-A1 NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS HPN, TMPRSS15, VIP LMNA 3429/4885PKM 3364/4885TSHR 4691/4885
US-20070032433-A1 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus HPN, TMPRSS15, VIP LMNA 3429/4885PKM 3364/4885TSHR 4691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.